Company Name GTC Biotherapeutics
Mailing Address 175 Crossing Blvd. Framingham, MA 01702
Company Description GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. ATryn, our recombinant form of human antithrombin, is the first transgenically produced protein to be approved anywhere in the world, having recently been approved by the European Commission for the prophylactic treatment of deep vein thrombosis in patients with hereditary antithrombin deficiencies that are undergoing surgical procedures.